Wendell David Associates Inc. Has $2.52 Million Holdings in Gilead Sciences, Inc. (GILD)

Wendell David Associates Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,168 shares of the biopharmaceutical company’s stock after selling 3,225 shares during the quarter. Wendell David Associates Inc.’s holdings in Gilead Sciences were worth $2,519,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Welch Investments LLC purchased a new stake in Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences in the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management boosted its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. 76.47% of the stock is currently owned by institutional investors.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.70 on Friday. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $105,390.00, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.70 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.83%. Gilead Sciences’s payout ratio is 59.77%.

Several brokerages have recently commented on GILD. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Leerink Swann decreased their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Mizuho boosted their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $87.04.

In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock valued at $32,742,108 over the last quarter. 1.30% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Wendell David Associates Inc. Has $2.52 Million Holdings in Gilead Sciences, Inc. (GILD)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://ledgergazette.com/2018/02/18/wendell-david-associates-inc-has-2-52-million-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply